{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:50:44Z","timestamp":1791175844950,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Clinical Virology"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1016\/j.jcv.2012.12.020","type":"journal-article","created":{"date-parts":[[2013,2,5]],"date-time":"2013-02-05T01:18:25Z","timestamp":1360027105000},"page":"13-18","source":"Crossref","is-referenced-by-count":89,"title":["Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors"],"prefix":"10.1016","volume":"57","author":[{"given":"Dennis","family":"Hernandez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nannan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Ueland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Monikowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"McPhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jcv.2012.12.020_bib0005","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1177\/0091270003258669","article-title":"Global burden of disease (GBD) for hepatitis C","volume":"44","year":"2004","journal-title":"J Clin Pharmacol"},{"issue":"Pt 11","key":"10.1016\/j.jcv.2012.12.020_bib0010","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1099\/vir.0.80401-0","article-title":"Genetic diversity and evolution of hepatitis C virus\u201415 years on","volume":"85","author":"Simmonds","year":"2004","journal-title":"J Gen Virol"},{"issue":"7","key":"10.1016\/j.jcv.2012.12.020_bib0015","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.trstmh.2005.09.009","article-title":"Prevalence of hepatitis C virus infection in north-eastern Brazil: a population-based study","volume":"100","author":"Zarife","year":"2006","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"3","key":"10.1016\/j.jcv.2012.12.020_bib0020","first-page":"323","article-title":"Geographical distribution of hepatitis C virus genotypes in India","volume":"45","author":"Das","year":"2002","journal-title":"Indian J Pathol Microbiol"},{"key":"10.1016\/j.jcv.2012.12.020_bib0025","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1471-2334-8-69","article-title":"Frequency distribution of hepatitis C virus genotypes in different geographical regions of Pakistan and their possible routes of transmission","volume":"8","author":"Idrees","year":"2008","journal-title":"BMC Infect Dis"},{"issue":"1\u20132","key":"10.1016\/j.jcv.2012.12.020_bib0030","first-page":"173","article-title":"Genotype distribution in chronic hepatitis C patients in Greece","volume":"58","author":"Stamouli","year":"2012","journal-title":"Clin Lab"},{"issue":"2","key":"10.1016\/j.jcv.2012.12.020_bib0035","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jcv.2008.02.001","article-title":"Changing HCV genotypes distribution in Poland\u2014relation to source and time of infection","volume":"42","author":"Chlabicz","year":"2008","journal-title":"J Clin Virol"},{"issue":"4","key":"10.1016\/j.jcv.2012.12.020_bib0040","first-page":"109","article-title":"Genotype distribution amongst hepatitis C patients in The Netherlands","volume":"64","author":"de Vries","year":"2006","journal-title":"Neth J Med"},{"issue":"4","key":"10.1016\/j.jcv.2012.12.020_bib0045","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/S0168-8278(94)80112-6","article-title":"Hepatitis C virus RNA and antibodies among blood donors in Beijing","volume":"21","author":"Wang","year":"1994","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.jcv.2012.12.020_bib0050","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1053\/j.gastro.2011.06.004","article-title":"Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3\/4A protease recombinant viruses","volume":"141","author":"Gottwein","year":"2011","journal-title":"Gastroenterology"},{"issue":"7294","key":"10.1016\/j.jcv.2012.12.020_bib0055","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature08960","article-title":"Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect","volume":"465","author":"Gao","year":"2010","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.jcv.2012.12.020_bib0060","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1128\/AAC.00307-11","article-title":"Mechanistic characterization of GS-9190 (Tegobuvir), a novel nonnucleoside inhibitor of hepatitis C virus NS5B polymerase","volume":"55","author":"Shih","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.jcv.2012.12.020_bib0065","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1053\/j.gastro.2007.02.037","article-title":"Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir","volume":"132","author":"Sarrazin","year":"2007","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.jcv.2012.12.020_bib0070","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1365-2893.2011.01449.x","article-title":"Mutations selected in the hepatitis C virus NS3 protease domain during sequential treatment with boceprevir with and without pegylated interferon alfa-2b","volume":"19","author":"Vermehren","year":"2012","journal-title":"J Viral Hepat"},{"issue":"6","key":"10.1016\/j.jcv.2012.12.020_bib0075","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1002\/hep.24609","article-title":"Multiple ascending dose study of BMS-790052, an NS5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1","volume":"54","author":"Nettles","year":"2011","journal-title":"Hepatology"},{"issue":"18","key":"10.1016\/j.jcv.2012.12.020_bib0080","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMoa0807650","article-title":"Telaprevir and peginterferon with or without ribavirin for chronic HCV infection","volume":"360","author":"H\u00e9zode","year":"2009","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.jcv.2012.12.020_bib0085","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1056\/NEJMoa0806104","article-title":"Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection","volume":"360","author":"McHutchison","year":"2009","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.jcv.2012.12.020_bib0090","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.jcv.2012.12.020_bib0095","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"Bacon","year":"2011","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jcv.2012.12.020_bib0100","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2011.05.046","article-title":"Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections","volume":"141","author":"Foster","year":"2011","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.jcv.2012.12.020_bib0105","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/hep.24641","article-title":"An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases","volume":"54","author":"Ghany","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jcv.2012.12.020_bib0110","first-page":"3","article-title":"Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2\/3","volume":"5","author":"Silva","year":"2011","journal-title":"Hepatol Int"},{"issue":"5","key":"10.1016\/j.jcv.2012.12.020_bib0115","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","article-title":"Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose","volume":"140","author":"Hadziyannis","year":"2004","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.jcv.2012.12.020_bib0120","article-title":"High rate of sustained virologic response with the all-oral combination of daclatasvir (NS5A inhibitor) plus sofosbuvir (nucleotide NS5B inhibitor), with or without ribavirin, in treatment-na\u00efve patients chronically infected with HCV genotype 1, 2, or 3","volume":"56","author":"Sulkowski","year":"2012","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.jcv.2012.12.020_bib0125","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1002\/hep.24594","article-title":"Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations","volume":"54","author":"Fridell","year":"2011","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.jcv.2012.12.020_bib0130","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1128\/AAC.00556-10","article-title":"Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system","volume":"54","author":"Fridell","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"S2","key":"10.1016\/j.jcv.2012.12.020_bib0135","first-page":"S473","article-title":"A description of virologic escape in HCV genotype 1-infected patients treated with daclatasvir (BMS-790052) in combination with ribavirin and peginterferon alfa-2a or peginterferon alfa-2b","volume":"56","author":"McPhee","year":"2012","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.jcv.2012.12.020_bib0140","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1002\/hep.25581","article-title":"Impact of a baseline polymorphism on the emergence of resistance to the hepatitis C virus nonstructural protein 5A replication complex inhibitor, BMS-790052","volume":"55","author":"Sun","year":"2012","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.jcv.2012.12.020_bib0145","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1128\/AAC.06169-11","article-title":"In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A","volume":"56","author":"Wang","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.jcv.2012.12.020_bib0150","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jhep.2011.12.029","article-title":"A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C","volume":"57","author":"Lawitz","year":"2012","journal-title":"J Hepatol"},{"issue":"10","key":"10.1016\/j.jcv.2012.12.020_bib0155","doi-asserted-by":"crossref","first-page":"5277","DOI":"10.1128\/JVI.02667-09","article-title":"Novel infectious cDNA clones of hepatitis C virus genotype 3a (strain S52) and 4a (strain ED43): genetic analyses and in vivo pathogenesis studies","volume":"84","author":"Gottwein","year":"2010","journal-title":"J Virol"},{"issue":"10","key":"10.1016\/j.jcv.2012.12.020_bib0160","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1093\/molbev\/msr121","article-title":"MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods","volume":"28","author":"Tamura","year":"2011","journal-title":"Mol Biol Evol"},{"issue":"3","key":"10.1016\/j.jcv.2012.12.020_bib0165","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/jmv.1055","article-title":"Sequence analysis of hepatitis C virus isolated from a fulminant hepatitis patient","volume":"64","author":"Kato","year":"2001","journal-title":"J Med Virol"},{"issue":"4","key":"10.1016\/j.jcv.2012.12.020_bib0170","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jcv.2012.04.024","article-title":"Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b","volume":"54","author":"Suzuki","year":"2012","journal-title":"J Clin Virol"},{"issue":"4","key":"10.1016\/j.jcv.2012.12.020_bib0175","first-page":"580A","article-title":"Characterization of HCV genotype 1 NS5A resistance variants from the phase 2b COMMAND-1 study: daclatasvir plus peginterferon-alfa\/ribavirin in treatment-naive patients","volume":"56","author":"Hernandez","year":"2012","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.jcv.2012.12.020_bib0180","first-page":"579A","article-title":"Characterization of HCV NS5A resistance variants in naive patients infected with genotypes 2 and 3 receiving short-term treatment of daclatasvir in combination with pegylated interferon-alfa and ribavirin","volume":"56","author":"McPhee","year":"2012","journal-title":"Hepatology"}],"updated-by":[{"DOI":"10.1016\/j.jcv.2016.02.008","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000}}],"container-title":["Journal of Clinical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653213000073?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653213000073?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,19]],"date-time":"2018-10-19T00:52:56Z","timestamp":1539910376000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1386653213000073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S1386653213000073"],"URL":"https:\/\/doi.org\/10.1016\/j.jcv.2012.12.020","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.jcv.2016.02.008","asserted-by":"object"}]},"ISSN":["1386-6532"],"issn-type":[{"value":"1386-6532","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]}}}